Skip to content

Welcome to Discover Pharma! Today is : October 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

MHRA

  • Clinical & Regulatory,Pharmaceuticals and therapeutics

    MHRA grants Promising Innovative Medicine designation to TransCon CNP for achondroplasia

    Ascendis Pharma UK Limited announced that TransCon CNP (navepegritide) has [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Digital & Data,Medical devices,Opinion & Events

    AI tool could spot hospital infections up to 72 hours early

    Sanome’s MEMORI becomes the first UK-developed AI medical device to [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain

    Symbiosis completes 1,000th batch of sterile injectable drug product

    Contract manufacturer Symbiosis Pharmaceutical Services has announced the completion of [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    MHRA approves Biogen’s tofersen for ultra-rare genetic form of motor neurone disease

    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Medical devices

    MHRA approval expected soon for non-surgical weight loss device RESET

    Morphic Medical’s non-invasive weight loss device RESET is expected to [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Opinion & Events

    NICE recommends Mirikizumab for moderately to severely active Crohn’s Disease after biologic failure

    Mirikizumab is now recommended by NICE for routine NHS use [...]

    May 5, 2026
  • Digital & Data,Drug Discovery & Development,Opinion & Events

    AI governance in pharmacovigilance: Marie Flanagan calls for safety-specific frameworks to safeguard patient risk

    The integration of artificial intelligence into pharmacovigilance is prompting a [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Opinion & Events

    NICE backs mirikizumab for treatment-resistant Crohn’s disease

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 5, 2026
Previous12

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • SurVaxM improves survival in Phase 2b glioblastoma trial
    Categories: Central Nervous System, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Lab-grown human neuromuscular junctions advance MND drug discovery
    Categories: Research & Development, Therapeutic Areas
  • Olink assay correlates with ELISA for measuring endothelin-1
    Categories: Clinical & Regulatory, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top